This clinical trial is focused on studying a type of cancer called high-risk diffuse large B-cell lymphoma (DLBCL). The treatment being tested is a medication known as atezolizumab, which is also referred to by its code name, RO5541267. Atezolizumab is given as a solution through an infusion, which means it is administered directly into the bloodstream.
The purpose of the study is to evaluate how effective atezolizumab is in maintaining remission in patients who have already responded well to initial treatment with a regimen called R-CHOP. This study will observe patients over a period of time to see if the cancer stays in remission, meaning it does not come back. Participants will receive atezolizumab after completing their initial treatment and will be monitored for any changes in their health status.
Throughout the study, researchers will keep track of the participants’ health, looking for any side effects and how the treatment affects their immune system. The study aims to understand the relationship between the treatment and the body’s immune response, as well as how it impacts the long-term health of the participants. The trial is expected to continue until early 2027, providing valuable insights into the potential benefits of atezolizumab for patients with high-risk DLBCL.
Belgium 
The Netherlands 
